Skip to Content

Dr Reddy's Laboratories Ltd ADR RDY

Morningstar Rating
$76.71 −0.38 (0.50%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Price vs Fair Value

RDY is trading at a 43% premium.
Price
$77.09
Fair Value
$38.00
Uncertainty
High
1-Star Price
$57.90
5-Star Price
$34.50
Economic Moat
Gmxph
Capital Allocation
Qnsddct

Bulls Say, Bears Say

Bulls

Generic versions of sizable drugs like Revlimid and Vascepa will help fuel Reddy’s top line.

Bears

Continued efforts from the Indian government to educate the public and roll out more non-branded generic drugs could act as a headwind for Dr. Reddy’s.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RDY is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$77.09
Day Range
$76.6877.14
52-Week Range
$52.5577.72
Bid/Ask
$76.58 / $76.76
Market Cap
$12.77 Bil
Volume/Avg
8,205 / 247,933

Key Statistics

Price/Earnings (Normalized)
20.75
Price/Sales
3.91
Dividend Yield (Trailing)
0.63%
Dividend Yield (Forward)
0.63%
Total Yield
0.63%

Company Profile

Dr. Reddy’s is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (22% of its generics sales), Russia (12%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy’s also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy’s has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy’s also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Large Growth
Total Number of Employees
22,822

Competitors

Valuation

Metric
RDY
TEVA
NVS
Price/Earnings (Normalized)
20.755.1115.01
Price/Book Value
4.021.964.48
Price/Sales
3.910.924.58
Price/Cash Flow
15.9410.1714.66
Price/Earnings
RDY
TEVA
NVS

Financial Strength

Metric
RDY
TEVA
NVS
Quick Ratio
1.800.540.88
Current Ratio
2.551.021.16
Interest Coverage
46.520.3910.94
Quick Ratio
RDY
TEVA
NVS

Profitability

Metric
RDY
TEVA
NVS
Return on Assets (Normalized)
15.57%6.70%12.15%
Return on Equity (Normalized)
21.70%39.00%27.10%
Return on Invested Capital (Normalized)
20.10%13.54%17.72%
Return on Assets
RDY
TEVA
NVS
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - Specialty & Generic Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
ZTS
Zoetis Inc Class AWthlp$91.5 Bil
MKKGY
Merck KGaA ADRLmxxl$74.9 Bil
HLN
Haleon PLC ADRTllkt$36.8 Bil
VTRS
Viatris IncDsps$14.7 Bil
TEVA
Teva Pharmaceutical Industries Ltd ADRRwh$14.7 Bil
CTLT
Catalent IncLbkfk$10.5 Bil
PRGO
Perrigo Co PLCFnjtr$3.6 Bil
CURLF
Curaleaf Holdings IncNjpwm$3.6 Bil
PBH
Prestige Consumer Healthcare IncJstqn$3.5 Bil

Sponsor Center